Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

Market Cap	1.11T
Revenue (ttm)	8.61B
Net Income (ttm)	-19.48B
Shares Out	30.01M
EPS (ttm)	-653.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70,737
Average Volume	120,039
Open	36,700
Previous Close	36,750
Day's Range	36,400 - 38,400
52-Week Range	25,450 - 42,700
Beta	0.39
RSI	50.76
Earnings Date	May 15, 2025

About Mezzion Pharma

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 17
• Stock Exchange: KOSDAQ
• Ticker Symbol: 140410

Financial Performance

In 2024, Mezzion Pharma's revenue was 8.61 billion, a decrease of -72.85% compared to the previous year's 31.72 billion. Losses were -19.48 billion, 53.0% more than in 2023.